First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
A phase 1/2 trial of Visugromab and Nivolumab in advanced solid tumours, run by CatalYm GmbH, active and no longer recruiting.
Overview
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) is a phase 1/2 interventional study registered as NCT04725474 by CatalYm GmbH, with 199 participants enrolled, started 2020-12-09 and due to reach its primary completion in 2028-04-30. Interventions recorded: visugromab (CTL-002) and nivolumab.
Similar pages
not linked directly; found by shared links- TrialStudy BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialVisugromab in Cachexia International Trial
Shares Visugromab, CatalYm.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTwo Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.